Laurion Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Laurion Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.02M	Sell	3,391 -1,040	-23%	-$314K	0.03%	246
2026 Q1	$1.47M	Buy	+4,431	New	+$1.51M	0.06%	233
2020 Q3	–	Sell	-6,013	Closed	-$891K	–	813
2020 Q2	$891K	Buy	+6,013	New	+$811K	0.01%	492
2019 Q1	–	Sell	-9,341	Closed	-$681K	–	831
2018 Q4	$681K	Buy	+9,341	New	+$718K	0.01%	645
2018 Q1	–	Sell	-121,735	Closed	-$15.5M	–	1305
2017 Q4	$15.5M	Buy	+121,735	New	+$15.3M	0.08%	255
2017 Q1	–	Sell	-9,450	Closed	-$354K	–	1267
2016 Q4	$354K	Buy	+9,450	New	+$396K	﹤0.01%	900

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Laurion Capital Management's ALNY Position: Q2 2026 in Review

Laurion Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 23% in Q2 2026, selling an estimated $314K and leaving 3,391 shares worth $1.02M. The position accounts for 0.03% of the portfolio, ranked #246.

Laurion Capital Management first reported a position in ALNY in Q4 2016 and has held it in 6 quarters since. The position peaked at $15.5M in Q4 2017. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Laurion Capital Management held 3,391 shares of Alnylam Pharmaceuticals worth $1.02M as of Q2 2026.
Laurion Capital Management sold 1,040 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $314K.
Alnylam Pharmaceuticals made up 0.03% of Laurion Capital Management's portfolio in Q2 2026, its #246 holding.
Laurion Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2016 and has held it in 6 quarters since.
Laurion Capital Management's Alnylam Pharmaceuticals position peaked at $15.5M in Q4 2017.
791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.